We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Alternative Cancer Treatments May Be Based on Green Tea Components

By LabMedica International staff writers
Posted on 10 Feb 2015
Print article
Image: Space-filling molecular model of epigallocatechin gallate (EGCG)(Photo courtesy of Wikimedia Commons).
Image: Space-filling molecular model of epigallocatechin gallate (EGCG)(Photo courtesy of Wikimedia Commons).
A recent paper suggested that the green tea component epigallocatechin-3-gallate (EGCG) could be developed into an alternative treatment for oral cancer that would not have the severe side effects of current chemotherapeutic agents.

EGCG is the most abundant catechin in tea and is a potent antioxidant that may have therapeutic applications in the treatment of many disorders. It is found in green tea but not black tea.

Investigators at Pennsylvania State University (University Park, USA) previously reported that EGCG could induce oxidative stress in oral cancer cells but exerted antioxidant effects in normal cells. Now, in a follow-up study, they treated cultures of human oral squamous carcinoma cells (SCC-25, SCC-9), pre-malignant leukoplakia cells (MSK-Leuk1), and normal human gingival fibroblast cells (HGF-1) with various doses of EGCG.

They reported in the November 17, 2015, online issue of the journal Molecular Nutrition and Food Research that EGCG suppressed sirtuin 3 (silent mating type information regulation 2 homolog 3 or SIRT3) mRNA and protein expression, as well as SIRT3 activity in SCC-25 cells, whereas it increased SIRT3 activity in HGF-1 cells. SIRT3 is the third member of the mammalian sirtuin family, which exhibits NAD+-dependent deacetylase activity.

EGCG selectively decreased the nuclear localization of the estrogen-related receptor alpha (ERRalpha), the transcription factor regulating SIRT3 expression, in SCC-25 cells. This indicated that EGCG might regulate SIRT3 transcription in oral cancer cells via ERRalpha. EGCG also differentially modulated the mRNA expressions of SIRT3-associated downstream targets including glutathione peroxidase 1 and superoxide dismutase 2 in normal and oral cancer cells.

"EGCG plays an important role in mitochondrial function and in anti-oxidant response in lots of tissues in the body, so the idea that EGCG might selectively affect the activity of sirtuin 3 in cancer cells—to turn it off—and in normal cells—to turn it on—is probably applicable in multiple kinds of cancers," said senior author Dr. Joshua D. Lambert, associate professor of food science at Pennsylvania State University. "EGCG is doing something to damage the mitochondria and that mitochondrial damage sets up a cycle causing more damage and it spirals out, until the cell undergoes programmed cell death. It looks like EGCG causes the formation of reactive oxygen species in cancer cells, which damages the mitochondria and the mitochondria responds by making more reactive oxygen species."

"The problem with a lot of chemotherapy drugs - especially early chemotherapy drugs - is that they really just target rapidly dividing cells, so cancer divides rapidly, but so do cells in your hair follicles and cells in your intestines, so you have a lot of side effects," said Dr. Lambert. "But you do not see these sorts of side effects with green tea consumption."

Related Links:

Pennsylvania State University


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
ELISA System
ABSOL HS DUO
New
Serum Toxicology Benzodiazepine Assay
DRI Serum Toxicology Benzodiazepine Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.